Wolfe Research initiated coverage of Immunovant with an Outperform rating and $55 price target. The firm views the current price as moderately suppressed, as investors may be undervaluing the self-administration formulation. In addition, Wolfe is excited about the catalyst path.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant remains top pick at Citi after year-to-date selloff
- Immunovant, Inc. Is Worried About This – Should You Be Worried Too?
- Immunovant options imply 3.5% move in share price post-earnings
- Immunovant remains attractive despite stock underperformance, says Wells Fargo
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
